Primary pancreatic lymphoma: Report of three cases with review of literature

Altaf Gauhar Haji,
Shekhar Sharma,
K. Abdul Majeed1,
D. K. Vijaykumar,
K. Pavithran2,
M. Dinesh3

Departments of Surgical Oncology, 1Medical Oncology and 2Radiation Oncology, Amrita Institute of Medical Sciences and Research Center, Ernakulam, Kerala, India

Address for correspondence:
Dr. Altaf Gauhar Haji,
Department of Surgical Oncology, Amrita Institute of Medical Sciences and Research Center, Ernakulam - 682 026,
Kerala, India.
E-mail: altafhaji786@yahoo.com

ABSTRACT

Background: Primary pancreatic lymphoma (PPL) is an extremely rare neoplasm, which may be confused with pancreatic adenocarcinoma. So far only about 150 cases of PPL have been reported. Materials and Methods: We present our experience of 3 cases of PPL over a 4-year period. Results: All the patients presented with vague abdominal pain of duration ranging from 1½ months to 3 months. Two patients had diagnosis confirmed histologically by CT-guided core biopsy or Fine needle aspiration procedure. We were able to avoid unnecessary laparotomy in 2 patients using preoperative guided Fine needle aspiration Cytology, although the third patient did undergo a Whipple’s procedure as the diagnosis of PPL was not considered during the initial workup. Conclusions: There is no significant difference noted with regard to patient’s age or duration of symptoms between patients with either pancreatic adenocarcinoma or PPL. The differential diagnosis of PPL includes pancreatic adenocarcinoma and secondary involvement of pancreas from extra-nodal lymphoma. Combination of two things is suggestive of Pancreatic lymphoma: (1) Bulky localized tumor in pancreatic head (2) Absence of significant dilatation of main pancreatic duct strengthens a diagnosis of pancreatic lymphoma over adenocarcinoma. Majority of patients can be managed with chemotherapy with much better prognosis compared to patients with pancreatic adenocarcinoma. Larger series of patients are needed to evaluate whether chemotherapy, eventually followed by involved-field radiation therapy, is the treatment of choice for PPL.

Key words: Pancreatic lymphoma, pancreatic adenocarcinoma, neoplasm

DOI: 10.4103/0971-5851.56331

INTRODUCTION

Gastrointestinal (GI) tract is the most common site of extra-nodal non-Hodgkin's lymphomas (NHLs), accounting for 15% to 20% of all NHL cases.[1] Although secondary involvement of pancreas is seen often in cases of GI lymphoma, primary pancreatic lymphoma (PPL) is an extremely rare disease that can mimic pancreatic carcinoma.[1,2] Fewer than 2% of extra-nodal malignant lymphomas and 0.5% of all pancreatic masses constitute PPL.[3,4] Significant, however, is the fact that PPLs are potentially treatable.[5]

To date, approximately 150 cases of PPL have been reported in the English-language medical literature.[6] There is no published data on PPL in the Indian population except for a single case report.[7]

MATERIALS AND METHODS

We present our experience of treating primary pancreatic lymphoma in patients at our hospital. Medical records of patients identified during a retrospective review of prospectively maintained database in the cancer institute of our hospital were retrieved after obtaining informed consent from the concerned patients. A pathologist reviewed slides and blocks to reconfirm the diagnosis. Literature was accessed on the Internet through PubMed search using the string ‘primary pancreatic lymphoma.’

RESULTS

Over a period of 4 years, we have diagnosed and treated 3 cases of primary pancreatic lymphoma [Table 1]. All the 3 patients presented with vague abdominal pain of duration ranging from 1½ months to 3 months. Other symptoms reported include low-grade fever in 2 patients, weight loss in 1, loss of appetite in 1 and melena in 1 patient. CT scan showed hypodense mass in body of pancreas (head and tail also in 1 case) encasing the vessels, peri-pancreatic lymph node enlargement with no bile or pancreatic duct dilatation [Figure 1] in all cases. These features are not very typical of a pancreatic malignancy. Two patients had diagnosis confirmed histologically by CT-guided core biopsy or FNA.
Haji, et al.: Primary pancreatic lymphoma

procedure. One patient underwent Whipple’s procedure before the diagnosis was made.

Hematoxylin and cosin–stained sections from tumor in all the 3 patients showed monotonous population of small round cells in sheets separated by sparse fibrous septae infiltrating the pancreatic parenchyma [Figure 2]. Neoplastic cells had scanty cytoplasm, coarse nuclear chromatin and prominent nucleoli. On immunohistochemistry, all the tumors were positive for CD 20 and negative for CD 3 and were typed as a diffuse large B cell lymphoma of the pancreas.

Two patients received chemotherapy (cyclophosphamide; adriamycin hydrochloride; vincristine and predinosolone — CHOP regimen) for 4 cycles followed by radiotherapy (45 Gy in 20 fractions for 1 patient and 30 Gy in 18 fractions for the other) using antero-posterior and postero-anterior pair beams. One patient who was diagnosed following Whipple’s procedure received adjuvant chemotherapy with CHOP regimen (6 cycles) alone.

All the patients are currently on follow-up (range, 1-36 months) and are so far free of disease recurrence.

**DISCUSSION**

Diagnostic criteria for PPL include presence of main mass in the pancreas with lymph nodal involvement confined to the peri-pancreatic region with no hepatic or splenic involvement; absence of superficial lymphadenopathy and mediastinal lymph node enlargement; and a normal leukocyte count in peripheral blood.[8,9]

Literature suggests a strong male predominance (male-to-female ratio, 7:1).[6,10] There is no significant difference noted with regard to patient’s age or duration of symptoms between pancreatic adenocarcinoma and PPL.[11-13]

Most common presenting symptom reported in literature is abdominal pain, found in about 83% of cases, followed by (in order of frequency) abdominal mass (58%), weight loss (50%), jaundice (37%), acute pancreatitis (12%), small-bowel obstruction (12%) and diarrhea (12%).[1,3,6,8,9] Obstructive jaundice seems to be less frequent in PPL than in pancreatic adenocarcinoma.[8,9] In this series, the most common presenting symptom was vague abdominal pain, as reported previously. One of our patients had low-grade fever, while another had melena, both of which have not been described in this setting.

Usual location of the tumor mass is in the head of the pancreas (more than 80%), with size ranging from
In our series, body of the pancreas was predinosolone; NED = No evidence of disease; * = Since completion of chemotherapy CHOP regimen = Cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone.

Homogeneous. Presence of calcification or necrosis is usually indicative of pathology other than non-Hodgkin's lymphoma. An accurate guided core biopsy for confirmation of diagnosis of PPL is considered a safe, rapid and easy procedure with high diagnostic accuracy. We were able to avoid unnecessary laparotomy in 2 patients.

All cases of PPL reported to date in western countries are of the B-cell type, but some cases of T-cell pancreatic lymphoma have been described in Japanese series. In our series, all the 3 cases were diffuse large B-cell type, akin to those described in western literature.

Chemotherapy, similar to that for non-Hodgkin's lymphoma, is the present standard treatment for most patients with PPL, with cure rates of up to 30%. The role of surgery is limited to rare occasions such as when FNA or core biopsy is nondiagnostic and open biopsy, therefore, is required. Total pancreatectomy (Whipple's procedure) is considered to have no impact on survival in a patient with PPL and, with its associated morbidity, is not generally recommended for PPL.

The role of radiation therapy in the management of PPL is not yet defined. Local radiotherapy up to total 40 Gy has been used as consolidation, but data is sparse to draw any conclusions.

Larger series of patients are needed to evaluate whether chemotherapy, eventually followed by involved-field radiation therapy, is the treatment of choice for PPL. Tumor burden, beta-2-microglobulin level above 2 mg/L and LDH level higher than normal are poor prognostic markers.

Anecdotal cases of elevated CA 19-9 levels in PPL have been reported. Chemotherapy, similar to that for non-Hodgkin’s lymphoma, is the present standard treatment for most patients with PPL, with cure rates of up to 30%.

## Table 1: Clinical and laboratory data of the 3 patients of primary pancreatic lymphoma

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Case I</th>
<th>Case II</th>
<th>Case III</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>65</td>
<td>63</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>Female</td>
<td>Male</td>
<td></td>
</tr>
<tr>
<td>Duration of symptoms</td>
<td>3 months</td>
<td>2 months</td>
<td>1.5 months</td>
<td></td>
</tr>
<tr>
<td>LDH</td>
<td>408.1</td>
<td>240</td>
<td>173.2</td>
<td>0-240 IU/L</td>
</tr>
<tr>
<td>Bilirubin (total)</td>
<td>2</td>
<td>4.2</td>
<td>6</td>
<td>0.2-1.0 mg/dL</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>98</td>
<td>121</td>
<td>128</td>
<td>39-117 IU/L</td>
</tr>
<tr>
<td>SGOT</td>
<td>42</td>
<td>58</td>
<td>71</td>
<td>5-38 IU/L</td>
</tr>
<tr>
<td>Amylase</td>
<td>68</td>
<td>78</td>
<td>143.5</td>
<td>28-100 IU/L</td>
</tr>
<tr>
<td>CA 19-9</td>
<td>78.1</td>
<td>111.8</td>
<td>62.2</td>
<td>0-37 IU/L</td>
</tr>
<tr>
<td>Diagnostic modality</td>
<td>CT scan and guided biopsy</td>
<td>CT scan and guided biopsy</td>
<td>Surgery (Whipple’s procedure)</td>
<td></td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>CHOP regimen</td>
<td>CHOP regimen</td>
<td>Adjuvant CHOP</td>
<td></td>
</tr>
<tr>
<td>Radiotherapy</td>
<td>45 Gy in 20 fractions</td>
<td>30 Gy in 18 fractions</td>
<td>Planned</td>
<td></td>
</tr>
<tr>
<td>Follow-up duration*</td>
<td>36 months</td>
<td>25 months</td>
<td>1 month</td>
<td></td>
</tr>
<tr>
<td>Status at last follow-up</td>
<td>NED</td>
<td>NED</td>
<td>NED</td>
<td></td>
</tr>
</tbody>
</table>

CHOP regimen = Cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone; NED = No evidence of disease; * = Since completion of chemotherapy

## Acknowledgements

Authors gratefully acknowledge the contribution of Dr. Ajith Nambiar, MD (Department of Pathology), for his help with review of slides.

## References

10. Nayer H, Weir EG, Sheth S, Ali SZ. Primary pancreatic...
Haji, et al.: Primary pancreatic lymphoma


Source of Support: Nil, Conflict of Interest: None declared.

Author Help: Reference checking facility

The manuscript system (www.journalonweb.com) allows the authors to check and verify the accuracy and style of references. The tool checks the references with PubMed as per a predefined style. Authors are encouraged to use this facility, before submitting articles to the journal.

- The style as well as bibliographic elements should be 100% accurate, to help get the references verified from the system. Even a single spelling error or addition of issue number/month of publication will lead to an error when verifying the reference.
- Example of a correct style
- Only the references from journals indexed in PubMed will be checked.
- Enter each reference in new line, without a serial number.
- Add up to a maximum of 15 references at a time.
- If the reference is correct for its bibliographic elements and punctuations, it will be shown as CORRECT and a link to the correct article in PubMed will be given.
- If any of the bibliographic elements are missing, incorrect or extra (such as issue number), it will be shown as INCORRECT and link to possible articles in PubMed will be given.